To Any American Who Owns a Cell Phone
If you own a cell phone, then mobile service providers hope you never get to see this video that could soon go viral.

His experiment could strike a bad chord with mobile phone companies. But you’ve got to see what this man discovered and what it means for phone users in the weeks ahead.

OTCMKTS:ALPMY - Astellas Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$17.55
▲ +0.15 (0.86%)
1 month | 3 months | 12 months
Get New Astellas Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPMY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.55.
Could This Be the Biggest US Gold Discovery in Years?
See how this tiny, unknown gold company secured a prime land package right next door to the world’s two largest gold producers in Nevada’s famed Carlin Trend where 84 Million gold ounces have already been extracted. Best of all, investors can still get in well below US$0.50 per share.
pixel

N/A

The current consensus among 0 investment analysts is to n/a stock in Astellas Pharma. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
1/23/2020Morgan StanleyInitiated CoverageOverweight
i
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
i
11/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
9/13/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
6/8/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral
i
7/7/2016UBS GroupInitiated CoverageBuy
i
(Data available from 6/14/2016 forward)
Astellas Pharma logo
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $17.55
$17.50
$17.62

50 Day Range

MA: $15.61
$14.72
$17.74

52 Week Range

Now: $17.55
$13.41
$17.78

Volume

47,500 shs

Average Volume

78,557 shs

Market Capitalization

$32.67 billion

P/E Ratio

28.77

Dividend Yield

1.54%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Astellas Pharma?

The following sell-side analysts have issued stock ratings on Astellas Pharma in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for ALPMY.

What is the current price target for Astellas Pharma?

0 Wall Street analysts have set twelve-month price targets for Astellas Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Astellas Pharma in the next year.
View the latest price targets for ALPMY.

What is the current consensus analyst rating for Astellas Pharma?

Astellas Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALPMY.

What other companies compete with Astellas Pharma?

How do I contact Astellas Pharma's investor relations team?

Astellas Pharma's physical mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company's listed phone number is 813-3244-3000. The official website for Astellas Pharma is www.astellas.com.

Could This Be the Biggest US Gold Discovery in Years?
See how this tiny, unknown gold company secured a prime land package right next door to the world’s two largest gold producers in Nevada’s famed Carlin Trend where 84 Million gold ounces have already been extracted. Best of all, investors can still get in well below US$0.50 per share.
pixel